Patients & Families

Psychiatric Disorders


Schizophrenia is a serious and complex syndrome with heterogeneous symptoms. As one of the leading causes of disability worldwide, it often results in significant emotional burden for those who experience symptoms, as well as their family and friends. It impacts 3.5 million people in the U.S. alone and more than 20 million people worldwide. In the U.S., there are approved treatment options for patients who experience positive symptoms of schizophrenia. Yet, roughly 50% of individuals diagnosed with schizophrenia remain untreated.

Major Depressive Disorder

More than 260 million people worldwide are affected by major depressive disorder (MDD), which is characterized by a persistently depressed mood or loss of interest in daily activities that can impact normal daily functioning, relationships, and overall quality of life. Treatments range from selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and antidepressants. Along with behavioral therapy, these medications benefit between 40–70% of people suffering from depression. One third of patients do not benefit adequately from these treatments.


Anhedonia is a major depressive disorder that results in an inability to gain pleasure from normally enjoyable experiences. It is a core symptom in depression and is also frequently seen in people suffering with bipolar depression, schizophrenia, substance-abuse disorders, Parkinson’s disease, diabetes, and coronary artery disease. Anhedonia has been associated with changes in neurotransmitter levels involved in the brain’s reward system.


At Neurocrine Biosciences, we have a robust pipeline of investigational therapies with the potential to address unmet clinical needs of patients living with neurological, endocrine and psychiatric disorders.

Learn More

While others walk away from neuroscience because of risk and complexity, our team persists, resulting in four FDA-approved therapies.

Learn More